Innovation and Development

Quirem Medical offers an innovative cancer therapy solution, comprised of QuiremSpheres® microspheres, a dedicated administration device and a CE-marked proprietary software platform called Q-Suite™. Quirem Medical has an ambitious development road map to continuously push the boundaries of the radioembolization discipline. At the heart of our proposition is the unique ability of the holmium microspheres to be imaged with unparalleled accuracy by SPECT and MR imaging. The multi-modality imaging possibilities allow for accurate evaluation of the microspheres distribution and the dose distribution. This enables physicians to determine the dose-to-tissue and dose-to-tumor shortly after a radioembolization procedure.

As outpatient treatment, QuiremSpheres® are injected by a catheter in the liver artery and are transported by the blood flow to the tumor(s). QuiremSpheres® microspheres contain the radioactive isotope holmium-166, which is a high-energy beta-emitting isotope with gamma emission. The half-life of holmium-166 is 26.8 hours. The microspheres have a specific diameter of 30 micrometers, which causes the radioactive microspheres to lodge preferentially in the microvasculature surrounding the tumor, maximising tumourcidal effects and minimising the effects on healthy liver parenchyma. Following administration, over 90% of the radiation is delivered in 4 days.

Once the microspheres have reached the tumor they will emit their beta radiation and destroy tumor cells, while the low-energy gamma radiation passes through and out of the body and can be imaged by gamma-cameras. This unique property makes it possible to image the exact distribution of QuiremSpheres® microspheres inside the patient. Moreover, since the metal holmium can be seen on a MRI, also high resolution images on both the distribution of QuiremSpheres® as well as the exact anatomical reference can be observed, resulting in detailed information about the dose that is given directly to the tumor tissue.

To quantify the distribution of QuiremSpheres® microspheres and support effective treatment planning & evaluation, Quirem Medical has developed proprietary dose quantification software, called Q-Suite™. This enables QuiremSpheres® to become a personalized cancer therapy resulting in the best quality of care for patients with liver tumors. Q-Suite™ is compatible with Windows 7 and 10 and allows for straightforward conversion of DICOM-formatted images into 3D dose distributions.

Quirem Medical and Terumo will fully support new customers with preparing for a first patient case. A first step would be to acquire a holmium permit for the hospital, to allow handling of the holmium-166 isotope. Once the permit is in place, we will provide an extensive training program (both off- and on-site) to the involved physicians and specialists (radiologists, nuclear medicine specialists, medical physicists and technicians). We will also support you in preparing all imaging systems and the installation of the Q-Suite™ software. QuiremSpheres® are administered by using a sophisticated and robust administration system that is easy to handle and will limit the patient and medical staff from radiation exposure during administration.

Images of a liver treated with QuiremSpheres®

MRI Quirem Spheres

Biodistribution of the microspheres measured with MRI

SPECT Quirem Spheres

Biodistribution of the microspheres measured with SPECT. MR imaging enables higher resolution compared with SPECT.

T₁-weigthed MRI

T₁-weighted MR image showing tumor tissue (dark areas) inside the liver. High concentrations of microspheres are found at most of the tumor locations.